Moderna (NASDAQ:MRNA) Trading 5.6% Higher – Time to Buy?

Moderna, Inc. (NASDAQ:MRNA)’s stock price traded up 5.6% during mid-day trading on Tuesday . The stock traded as high as $187.20 and last traded at $182.56. 23,758,405 shares were traded during trading, an increase of 101% from the average daily volume of 11,791,728 shares. The stock had previously closed at $172.94.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Phase 3 INTerpath-001 results for intismeran autogene plus Merck’s Keytruda in high-risk melanoma previously met the trial’s endpoints. The positive outcome has become the primary catalyst behind Moderna’s roughly 510% one-year advance. Was Moderna Stock’s Cancer Vaccine Run Visible in Advance?
• Positive Sentiment: Detailed Phase 3 melanoma data will be presented at a Presidential Symposium during the European Society for Medical Oncology (ESMO) Congress on October 24. The prominent presentation slot is increasing investor confidence that the results could be clinically meaningful. Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
• Positive Sentiment: Moderna will provide three ESMO abstracts covering melanoma and updates involving the personalized therapy in pancreatic and lung cancers, broadening the potential opportunity beyond the initial indication. Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress
• Positive Sentiment: Investors are also positioning ahead of a late-October data release and Moderna’s October 24 investor webcast, which could offer further validation for personalized cancer treatment at scale. Moderna Adds Another 5% and Is Up 500% in 2026

Analysts Set New Price Targets

A number of brokerages have issued reports on MRNA. Barclays increased their price target on Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday, August 24th. Brookline Capital Markets reaffirmed a “buy” rating on shares of Moderna in a research note on Wednesday, August 19th. Rothschild & Co Redburn cut Moderna from a “neutral” rating to a “sell” rating and boosted their price objective for the stock from $40.00 to $81.00 in a research note on Thursday, September 3rd. Bank of America raised Moderna from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 19th. Finally, William Blair began coverage on shares of Moderna in a research note on Friday, August 28th. They issued an “outperform” rating for the company. Seven investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $76.72.

Moderna Price Performance

The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The stock has a market cap of $72.89 billion, a PE ratio of -22.85 and a beta of 1.10. The firm’s 50-day moving average price is $101.83 and its two-hundred day moving average price is $71.16.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The business had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same period last year, the business posted ($2.13) EPS. The business’s revenue was up 2.1% compared to the same quarter last year. On average, equities analysts expect that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO James M. Mock sold 34,836 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at $7,985,343.75. The trade was a 36.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider directly owned 74,129 shares in the company, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 118,882 shares of company stock valued at $16,862,280. 10.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Moderna in the 2nd quarter valued at $2,142,877,000. Capital World Investors purchased a new position in shares of Moderna in the 4th quarter valued at about $378,299,000. Theleme Partners LLP acquired a new position in shares of Moderna during the 2nd quarter worth approximately $564,272,000. Norges Bank acquired a new position in Moderna during the fourth quarter worth $79,707,000. Finally, Wellington Management Group LLP raised its position in shares of Moderna by 4.4% during the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after purchasing an additional 103,977 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.